Literature DB >> 16909029

Promises and challenges in developing RNAi as a research tool and therapy for neurodegenerative diseases.

Xu Gang Xia1, Hongxia Zhou, Zuoshang Xu.   

Abstract

RNA interference (RNAi) is a recently discovered mechanism that is conserved in a wide range of eukaryotic species. Triggered by double-stranded RNA, RNAi identifies and destroys the mRNA that shares homology with the double-stranded RNA. Because of its specificity, RNAi has a high potential for being a powerful investigative and therapeutic tool. Indeed, its use as a reverse genetics tool to determine gene functions in invertebrates and cultured mammalian cells has already been experiencing an explosive growth. Gratifyingly we have also seen its application in dissecting neurodegeneration pathways in vitro. Although early studies suggested that RNAi could be readily adapted for in vivo studies in mammals using the transgenic technology, difficulties including low transgenicity and low RNAi efficacy have emerged, which has prevented the wide use of transgenic RNAi. The potential of RNAi therapy for human diseases has been a great source of excitement. Several new studies have demonstrated this concept in animal models of neurodegenerative disease. In this review, we highlight the recent literature and our own data in applying RNAi in research and therapy in the area of neurodegenerative diseases. We discuss the present and future challenges in the full realization of the potential for RNAi.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16909029     DOI: 10.1159/000089629

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  9 in total

Review 1.  Transgenic RNAi: Accelerating and expanding reverse genetics in mammals.

Authors:  Xu-Gang Xia; Hongxia Zhou; Zuoshang Xu
Journal:  Transgenic Res       Date:  2006-06       Impact factor: 2.788

2.  A tightly regulated Pol III promoter for synthesis of miRNA genes in tandem.

Authors:  Hongxia Zhou; Cao Huang; Xu Gang Xia
Journal:  Biochim Biophys Acta       Date:  2008-04-07

3.  RNAi: a novel strategy for the treatment of prion diseases.

Authors:  Qingzhong Kong
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

4.  RNA interference-produced autoregulation of inducible nitric oxide synthase expression.

Authors:  Chenzhuo Feng; Lin Cao; Zhiyi Zuo
Journal:  FEBS Lett       Date:  2011-07-04       Impact factor: 4.124

5.  Neutrophil-selective CD18 silencing using RNA interference in vivo.

Authors:  Xavier Cullere; Michael Lauterbach; Naotake Tsuboi; Tanya N Mayadas
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

6.  Pol II-expressed shRNA knocks down Sod2 gene expression and causes phenotypes of the gene knockout in mice.

Authors:  Xu-Gang Xia; Hongxia Zhou; Enrique Samper; Simon Melov; Zuoshang Xu
Journal:  PLoS Genet       Date:  2006-01-27       Impact factor: 5.917

7.  siRecords: a database of mammalian RNAi experiments and efficacies.

Authors:  Yongliang Ren; Wuming Gong; Haiyan Zhou; Yejun Wang; Feifei Xiao; Tongbin Li
Journal:  Nucleic Acids Res       Date:  2008-11-07       Impact factor: 16.971

8.  A construct with fluorescent indicators for conditional expression of miRNA.

Authors:  Linghua Qiu; Hongyan Wang; Xugang Xia; Hongxia Zhou; Zuoshang Xu
Journal:  BMC Biotechnol       Date:  2008-10-07       Impact factor: 2.563

9.  Autoregulation of inducible nitric oxide synthase expression by RNA interference provides neuroprotection in neonatal rats.

Authors:  Zhi Wang; Chenzhuo Feng; Huijuan Zhao; Xiaoyan Ren; Shuling Peng; Zhiyi Zuo
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.